Publications
Here you can browse the complete list of publications for studies listed on CDAS.
| Title | PubMed | Authors | Journal | Year | Studies |
|---|---|---|---|---|---|
| Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. | 29114854 | Reger MK, Zollinger TW, Liu Z, Jones JF, Zhang J | Int. J. Cancer | 2017 | PLCO |
| Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. | 28376197 | Kreimer AR, Johansson M, Yanik EL, Katki HA, Check DP, Lang Kuhs KA, Willhauck-Fleckenstein M, Holzinger D, Hildesheim A, Pfeiffer R, Williams C, Freedman ND, Huang WY, Purdue MP, Michel A, Pawlita M, Brennan P, Waterboer T | J. Natl. Cancer Inst. | 2017 | PLCO |
| Prospective study of DNA methylation at chromosome 8q24 in peripheral blood and prostate cancer risk. | 28463958 | Barry KH, Moore LE, Sampson JN, Koutros S, Yan L, Meyer A, Reddy M, Oler AJ, Cook MB, Fraumeni JF, Yeager M, Amundadottir LT, Berndt SI | Br. J. Cancer | 2017 | PLCO |
| Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. | 28702814 | Han SS, Erdogan SA, Toumazis I, Leung A, Plevritis SK | Cancer Causes Control | 2017 | PLCO |
| Vasectomy and Risk of Prostate Cancer in a Screening Trial. | 28830873 | Shoag J, Savenkov O, Christos PJ, Mittal S, Halpern JA, Askin G, Shoag D, Golan R, Lee DJ, O'Malley P, Najari B, Eisner B, Hu JC, Scherr D, Schlegel P, Barbieri CE | Cancer Epidemiol. Biomarkers Prev. | 2017 | PLCO |
| Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. | 28869989 | Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R | Ann. Intern. Med. | 2017 | PLCO |
| Early detection versus primary prevention in the PLCO flexible sigmoidoscopy screening trial: Which has the greatest impact on mortality? | 28976536 | Doroudi M, Schoen RE, Pinsky PF | Cancer | 2017 | PLCO |
| Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. | 29061540 | Halpern JA, Oromendia C, Shoag JE, Mittal S, Cosiano MF, Ballman KV, Vickers AJ, Hu JC | J. Urol. | 2017 | PLCO |
| Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival. | 29156299 | Temkin SM, Miller EA, Samimi G, Berg CD, Pinsky P, Minasian L | Eur. J. Cancer | 2017 | PLCO |
| The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. | 29211316 | de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R | Cancer | 2017 | PLCO |
| Body weight trajectories and risk of oesophageal and gastric cardia adenocarcinomas: a pooled analysis of NIH-AARP and PLCO Studies. | 28196067 | Petrick JL, Kelly SP, Liao LM, Freedman ND, Graubard BI, Cook MB | Br. J. Cancer | 2017 | PLCO |
| Effectiveness of flexible sigmoidoscopy screening in men and women and different age groups: pooled analysis of randomised trials. | 28087510 | Holme Ø, Schoen RE, Senore C, Segnan N, Hoff G, Løberg M, Bretthauer M, Adami HO, Kalager M | BMJ | 2017 | PLCO |
| Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. | 28376113 | Ten Haaf K, Jeon J, Tammemägi MC, Han SS, Kong CY, Plevritis SK, Feuer EJ, de Koning HJ, Steyerberg EW, Meza R | PLoS Med. | 2017 | NLST, PLCO |
| The association between Dietary Inflammatory Index scores and the prevalence of colorectal adenoma. | 28345504 | Haslam A, Wagner Robb S, Hébert JR, Huang H, Wirth MD, Shivappa N, Ebell MH | Public Health Nutr | 2017 | PLCO |
| Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men. | 28369777 | Layne TM, Weinstein SJ, Graubard BI, Ma X, Mayne ST, Albanes D | Cancer | 2017 | PLCO |
| A Novel Approach for Pathway Analysis of GWAS Data Highlights Role of BMP Signaling and Muscle Cell Differentiation in Colorectal Cancer Susceptibility - Erratum. | 28228184 | Mishra A, MacGregor S | Twin Res Hum Genet | 2017 | PLCO |
| On estimation of time-dependent attributable fraction from population-based case-control studies. | 28099992 | Zhao W, Chen YQ, Hsu L | Biometrics | 2017 | PLCO |
| Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. | 28139693 | Hoffmann TJ, Passarelli MN, Graff RE, Emami NC, Sakoda LC, Jorgenson E, Habel LA, Shan J, Ranatunga DK, Quesenberry CP, Chao CR, Ghai NR, Aaronson D, Presti J, Nordström T, Wang Z, Berndt SI, Chanock SJ, Mosley JD, Klein RJ, Middha M, Lilja H, Melan… | Nat Commun | 2017 | PLCO |
| Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. | 29117387 | Conti DV, Wang K, Sheng X, Bensen JT, Hazelett DJ, Cook MB, Ingles SA, Kittles RA, Strom SS, Rybicki BA, Nemesure B, Isaacs WB, Stanford JL, Zheng W, Sanderson M, John EM, Park JY, Xu J, Stevens VL, Berndt SI, Huff CD, Wang Z, Yeboah ED, Tettey Y, B… | J. Natl. Cancer Inst. | 2017 | PLCO |
| TET2 binds the androgen receptor and loss is associated with prostate cancer. | 27819678 | Nickerson ML, Das S, Im KM, Turan S, Berndt SI, Li H, Lou H, Brodie SA, Billaud JN, Zhang T, Bouk AJ, Butcher D, Wang Z, Sun L, Misner K, Tan W, Esnakula A, Esposito D, Huang WY, Hoover RN, Tucker MA, Keller JR, Boland J, Brown K, Anderson SK, Moore… | Oncogene | 2017 | PLCO |